Mga Batayang Estadistika
| CIK | 1522602 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CohBar, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 6, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 1, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 25, 2023 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 25, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 25, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| October 6, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Co |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Co |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 4, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| September 12, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-273101 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT –––––––––––––––––––––––––––––––––––––– To the Stockholders of CohBar, Inc. and Morphogenesis, Inc., CohBar, Inc., a Delaware corporation (“CohBar”), and Morphogenesis, Inc., a Delaware corporation (“Morphogenesis”), entered into an Agreement and Plan of Merger, as amended from time to time (the |
|
| September 12, 2023 |
As filed with the Securities and Exchange Commission on September 12, 2023 As filed with the Securities and Exchange Commission on September 12, 2023 No. 333-273101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 –––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 3 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 –––––––––––––––––––––––––––––––––––––– COHBAR, INC. (Exact name of registrant as specified in its charter) –––––––– |
|
| September 12, 2023 |
Exhibit 99.1 |
|
| September 12, 2023 |
CohBar, Inc. 1455 Adams Drive Suite 1308 Menlo Park, CA 94025 (650) 446-7888 September 12, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attn: Franklin Wyman Angela Connell Lauren S. Hamill Joe McCann Re: CohBar, Inc. Registration Statement on Form S-4 (File No. 333-273101) Ladies and |
|
| August 30, 2023 |
Exhibit 10.28 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT is made and entered into on April 23, 2021 (hereinafter “EFFECTIVE DATE”) by and between H. Lee Moffitt Cancer Center and Research |
|
| August 30, 2023 |
Exhibit 10.29 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Restated and Amended Exclusive License Agreement (“Agreement”), to be effective as of September 7, 2022 (“Effective Date |
|
| August 30, 2023 |
Exhibit 99.1 |
|
| August 30, 2023 |
As filed with the Securities and Exchange Commission on August 29, 2023 As filed with the Securities and Exchange Commission on August 29, 2023 No. 333-273101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 –––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 2 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 –––––––––––––––––––––––––––––––––––––– COHBAR, INC. (Exact name of registrant as specified in its charter) ––––––––––– |
|
| August 29, 2023 |
Gibson, Dunn & Crutcher LLP 555 Mission Street San Francisco, CA 94105-0921 Tel 415. |
|
| August 14, 2023 |
CohBar Reports Second Quarter 2023 Financial Results Exhibit 99.1 CohBar Reports Second Quarter 2023 Financial Results MENLO PARK, Calif., August 14, 2023 – CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results ● Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 14, 2023 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2023 |
Exhibit 10.29 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED RESTATED AND AMENDED EXCLUSIVE LICENSE AGREEMENT This Restated and Amended Exclusive License Agreement (“Agreement”), to be effective as of September 7, 2022 (“Effective Date |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 As filed with the Securities and Exchange Commission on August 10, 2023 No. 333-273101 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 –––––––––––––––––––––––––––––––––––––– AMENDMENT NO. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 –––––––––––––––––––––––––––––––––––––– COHBAR, INC. (Exact name of registrant as specified in its charter) ––––––––––– |
|
| August 10, 2023 |
Gibson, Dunn & Crutcher LLP 555 Mission Street San Francisco, CA 94105-0921 Tel 415. |
|
| August 10, 2023 |
Exhibit 10.27 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT is made and entered into on March 29, 2019 (hereinafter “EFFECTIVE DATE”) by and between H. Lee Moffitt Cancer Center and Research |
|
| August 10, 2023 |
Exhibit 10.28 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED EXCLUSIVE LICENSE AGREEMENT THIS AGREEMENT is made and entered into on April 23, 2021 (hereinafter “EFFECTIVE DATE”) by and between H. Lee Moffitt Cancer Center and Research |
|
| August 10, 2023 |
Exhibit 10.30 Asset Purchase Agreement by and between TuHURA Biopharma Inc. and MORPHOGENESIS, INC. Dated as of January 26, 2023 TABLE OF CONTENTS Page Article I PURCHASE AND SALE 1 Section 1.01 Purchase and Sale of Assets 1 Section 1.02 Excluded Assets 2 Section 1.03 Assumed Liabilities 2 Section 1.04 Excluded Liabilities 3 Section 1.05 Purchase Price 3 Section 1.06 Payment of the Purchase Price |
|
| July 3, 2023 |
FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.24 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (this “Agreement”) is made this 22nd day of May, 2023 by and between James Bianco, MD (“Employee”), and Morphogenesis, Inc. (the “Company”). Employee and the Company are hereinafter sometimes referred to individually as a “Party” and collectively as the “Parties.” This Agreement amend |
|
| July 3, 2023 |
Exhibit 99.6 Consent of Proposed Director I, George Ng., hereby consent to the following: ● to serve as a director of CohBar, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated May 22, 2023, by and among CohBar, Inc., Chimera MergeCo, Inc., and Morphogenesis, Inc., are consummated, including the merger of Morphogenesis, Inc. wi |
|
| July 3, 2023 |
MORPHOGENESIS, INC. STOCK OPTION AGREEMENT Exhibit 10.22 MORPHOGENESIS, INC. STOCK OPTION AGREEMENT THIS STOCK OPTION AGREEMENT (this “Option Agreement”) is entered into as of [] (the “Grant Date”) between Morphogenesis, Inc., a Florida corporation (the “Company”), and [] (the “Optionee). This option is being granted pursuant to the terms of the Company’s 2019 Restated Stock Option Plan, as the same may be amended from time to time (the “P |
|
| July 3, 2023 |
FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.23 FIRST AMENDED AND RESTATED EMPLOYMENT AGREEMENT This First Amended and Restated Employment Agreement (this “Agreement”) is made this 22nd day of May, 2023 by and between Dan Dearborn (“Employee”) and Morphogenesis, Inc. (the “Company”). Employee and the Company are hereinafter sometimes referred to individually as a “Party” and collectively as the “Parties.” This Agreement amends and |
|
| July 3, 2023 |
Consent of Ladenburg Thalmann & Co. Inc. Exhibit 99.7 Consent of Ladenburg Thalmann & Co. Inc. June 27, 2023 Board of Directors CohBar, Inc. 1455 Adams Drive, Suite 1308 Menlo Park, CA 94025 Re: Registration Statement on Form S-4 of CohBar, Inc. Members of the Board: We hereby consent to the inclusion of our opinion letter, dated May 22, 2023, to the Board of Directors of CohBar, Inc. (“CohBar”) as Annex G to, and to the reference theret |
|
| July 3, 2023 |
COMMON STOCK PURCHASE WARRANT MORPHOGENESIS, INC. Exhibit 4.11 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE |
|
| July 3, 2023 |
EXHIBIT 3.6 BYLAWS OF MORPHOGENESIS, INC. (As adopted by unanimous vote of the Board of Directors effective April 27, 2023) The provisions of these bylaws are subject and subordinate to the corporation’s certificate of incorporation. If any provisions of these bylaws are in conflict with the provisions of the certificate of incorporation, the provisions of the certificate of incorporation shall co |
|
| July 3, 2023 |
AMENDMENT TO WYLDKATZ, LLC CONSULTING AGREEMENT WITH MORPHOGENESIS, INC. Exhibit 10.26 AMENDMENT TO WYLDKATZ, LLC CONSULTING AGREEMENT WITH MORPHOGENESIS, INC. The undersigned, being the Principals of Wyldkatz, LLC, a Florida limited liability company, and Morphogenesis, Inc, (the “Company”) a Florida corporation hereby amend their Consulting Agreement dated July 1, 2021. The amendment shall solely consist of the following replacement of Section 3A: Term. This Agreemen |
|
| July 3, 2023 |
Amended & Restated EQUITY INCENTIVE PLAN Morphogenesis, Inc. Adopted on January 13, 2019 Exhibit 10.21 Amended & Restated EQUITY INCENTIVE PLAN Morphogenesis, Inc. Adopted on January 13, 2019 1. Purpose The purpose of this Amended and Restated Equity Incentive Plan (the “Plan”) of Morphogenesis, Inc., a Florida corporation (the “Company”), is to amend, update and restate the terms of the existing 2016 Stock Option Plan to advance the interests of the Company’s stockholders by enhancin |
|
| July 3, 2023 |
COMMON STOCK PURCHASE WARRANT MORPHOGENESIS, INC. Exhibit 4.9 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER |
|
| July 3, 2023 |
Exhibit 99.5 Consent of Proposed Director I, Alan List, M.D., hereby consent to the following: ● to serve as a director of CohBar, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated May 22, 2023, by and among CohBar, Inc., Chimera MergeCo, Inc., and Morphogenesis, Inc., are consummated, including the merger of Morphogenesis, In |
|
| July 3, 2023 |
Exhibit 99.4 Consent of Proposed Director I, James Bianco, M.D., hereby consent to the following: ● to serve as a director of CohBar, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated May 22, 2023, by and among CohBar, Inc., Chimera MergeCo, Inc., and Morphogenesis, Inc., are consummated, including the merger of Morphogenesis, |
|
| July 3, 2023 |
COMMON STOCK PURCHASE WARRANT OF MORPHOGENESIS, INC. Exhibit 4.13 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE |
|
| July 3, 2023 |
Morphogenesis, Inc. CONSULTING AGREEMENT Exhibit 10.25 Morphogenesis, Inc. CONSULTING AGREEMENT This CONSULTING AGREEMENT (“Agreement”) is made and entered into effective as of July 1, 2021 (the “Effective Date”) by and between MORPHOGENESIS INC., a Florida corporation (the “Company”) and WYALDKATZ, LLC, a Florida limited liability company (“Consultant”) (each being a “Party” hereto and together constituting the “Parties”). Dr. Patricia |
|
| July 3, 2023 |
CERTIFICATE OF INCORPORATION MORPHOGENESIS, INC. Exhibit 3.5 CERTIFICATE OF INCORPORATION OF MORPHOGENESIS, INC. I. NAME The name of the corporation is Morphogenesis, Inc. (the “Corporation”). II. REGISTERED OFFICE AND AGENT The address of the Corporation’s registered office is 251 Little Falls Drive, Wilmington, DE 19808, New Castle County. The name of the registered agent at such address is Corporation Service Company. III. PURPOSE The nature |
|
| July 3, 2023 |
As filed with the Securities and Exchange Commission on June 30, 2023 As filed with the Securities and Exchange Commission on June 30, 2023 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 –––––––––––––––––––––––––––––––––––––– FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 –––––––––––––––––––––––––––––––––––––– COHBAR, INC. (Exact name of registrant as specified in its charter) –––––––––––––––––––––––––––––––––––––– |
|
| July 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) CohBar, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| July 3, 2023 |
Exhibit 99.3 Consent of Proposed Director I, James Manuso, hereby consent to the following: ● to serve as a director of CohBar, Inc., to be renamed TuHURA Biosciences, Inc., if the transactions contemplated by the Agreement and Plan of Merger, dated May 22, 2023, by and among CohBar, Inc., Chimera MergeCo, Inc., and Morphogenesis, Inc., are consummated, including the merger of Morphogenesis, Inc. |
|
| July 3, 2023 |
COMMON STOCK PURCHASE WARRANT OF MORPHOGENESIS, INC. Exhibit 4.12 NEITHER THE ISSUANCE OF THIS WARRANT NOR THE ISSUANCE OF THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAS BEEN REGISTERED UNDER THE ACT OR ANY APPLICABLE STATE LAWS REGULATING THE SALE OF SECURITIES. NO INTEREST IN THIS WARRANT MAY BE SOLD, TRANSFERRED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE DISTRIBUTED UNLESS (I) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDE |
|
| July 3, 2023 |
Exhibit 4.10 WARRANT No.A-[] This Warrant and the securities issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Act”), or qualified under any state or foreign securities laws and may not be offered for sale, sold, pledged, hypothecated or otherwise transferred or assigned unless (i) a registration statement covering such shares is eff |
|
| June 5, 2023 |
Filed by CohBar, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: CohBar, Inc. (Commission File No. 001-38326) Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor |
|
| May 31, 2023 |
Filed by CohBar, Inc. Pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: CohBar, Inc. (Commission File No. 001-38326) Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual |
|
| May 23, 2023 |
Exhibit 99.2 |
|
| May 23, 2023 |
THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.7 THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Third Amendment to Executive Employment Agreement (this “Amendment”), dated as of May 22, 2023, amends that certain Executive Employment Agreement (the “Agreement”), dated as of November 27, 2013, as amended by that Amendment to Executive Employment Agreement, dated as of July 11, 2016, by and between CohBar, Inc., a Delaware corp |
|
| May 23, 2023 |
THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.7 THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Third Amendment to Executive Employment Agreement (this “Amendment”), dated as of May 22, 2023, amends that certain Executive Employment Agreement (the “Agreement”), dated as of November 27, 2013, as amended by that Amendment to Executive Employment Agreement, dated as of July 11, 2016, by and between CohBar, Inc., a Delaware corp |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 23, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among COHBAR, INC., CHIMERA MERGECO, INC. and MORPHOGENESIS, INC. Dated as of May 22, 2023 TABLE OF CONTENTS Page Article I CERTAIN GOVERNANCE MATTERS 3 Section 1.1 Parent Matters 3 Section 1.2 Surviving Company Matters 3 Article II THE MERGER 4 Section 2.1 Incorporation of Merger Sub 4 Section 2.2 The Merger 4 Section 2.3 Closing 4 Section 2.4 Effec |
|
| May 23, 2023 |
[Remainder of page intentionally left blank.] Exhibit 10.9 May 22, 2023 Mr. Jeffrey F. Biunno Chief Financial Officer CohBar, Inc. Re: CohBar, Inc. Employee Retention Bonus Ladies and Gentlemen: Reference is made to that certain Executive Employment Agreement, dated as of November 27, 2013, as amended (the “Employment Agreement”) by and between CohBar, Inc., a Delaware corporation (the “Company”) and Jeff Biunno (“you”). It is proposed that t |
|
| May 23, 2023 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is dated as of May 22, 2023, by and between CohBar, Inc., a Delaware corporation (the “Company”) and K&V Investment Two, LLC, a Florida limited liability company (including its successors and assigns, the “Purchaser”). BACKGROUND: A. The Company and the Purchaser are executing and delivering this Agreement in re |
|
| May 23, 2023 |
Exhibit 99.1 CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy ● Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulators ● Lead |
|
| May 23, 2023 |
Exhibit 99.2 |
|
| May 23, 2023 |
FORM OF LOCK-UP AGREEMENT LOCK-UP AGREEMENT Exhibit 10.5 FORM OF LOCK-UP AGREEMENT LOCK-UP AGREEMENT May 22, 2023 CohBar, Inc. 1455 Adams Drive, Suite 1308 Menlo Park, California 94025 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that CohBar, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of May 22, 2023 (as the same may |
|
| May 23, 2023 |
FORM OF COMPANY SUPPORT AGREEMENT MORPHOGENESIS, INC. SUPPORT AGREEMENT Exhibit 10.3 FORM OF COMPANY SUPPORT AGREEMENT MORPHOGENESIS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of May 22, 2023 (the “Effective Date”), is made by and among CohBar, Inc., a Delaware corporation (“Parent”), Morphogenesis, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the |
|
| May 23, 2023 |
FORM OF LOCK-UP AGREEMENT LOCK-UP AGREEMENT Exhibit 10.5 FORM OF LOCK-UP AGREEMENT LOCK-UP AGREEMENT May 22, 2023 CohBar, Inc. 1455 Adams Drive, Suite 1308 Menlo Park, California 94025 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that CohBar, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of May 22, 2023 (as the same may |
|
| May 23, 2023 |
FORM OF COMPANY SUPPORT AGREEMENT MORPHOGENESIS, INC. SUPPORT AGREEMENT Exhibit 10.3 FORM OF COMPANY SUPPORT AGREEMENT MORPHOGENESIS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of May 22, 2023 (the “Effective Date”), is made by and among CohBar, Inc., a Delaware corporation (“Parent”), Morphogenesis, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of the |
|
| May 23, 2023 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (this “Agreement”) is dated as of May 22, 2023, by and between CohBar, Inc., a Delaware corporation (the “Company”) and K&V Investment Two, LLC, a Florida limited liability company (including its successors and assigns, the “Purchaser”). BACKGROUND: A. The Company and the Purchaser are executing and delivering this Agreement in re |
|
| May 23, 2023 |
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 10.6 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2023, is entered into by and among CohBar, Inc., a Delaware corporation (“Public Company”), and [●], as initial Rights Agent (as defined herein). RECITALS WHEREAS, Public Company, Chimera MergeCo, Inc., a Delaware corporation and wholly owned subsidiary of Public Compa |
|
| May 23, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of [], 2023, by and among CohBar, Inc., a Delaware corporation (the “Company”), K&V Investment Two, LLC, a Florida limited liability company and the Warrant Holders (as defined below). This Agreement is made pursuant to the Stock Purchase Agreement, dated as of May 22, 2023, between the Com |
|
| May 23, 2023 |
Exhibit 99.3 CohBar and Morphogenesis Merger Agreement Announcement Webcast Call Transcript TUESDAY, MAY 23, 2023 8:30am CORPORATE PARTICIPANTS Dr. Joseph J. Sarret, President and Chief Executive Officer of CohBar Dr. James Bianco, Chief Executive Officer of Morphogenesis PRESENTATION Operator Slide 1 Hello, and welcome to the CohBar and Morphogenesis conference call and webcast. As a brief remind |
|
| May 23, 2023 |
FORM OF PARENT SUPPORT AGREEMENT COHBAR, INC. SUPPORT AGREEMENT Exhibit 10.4 FORM OF PARENT SUPPORT AGREEMENT COHBAR, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of May 22, 2023 (the “Effective Date”), is made by and among CohBar, Inc., a Delaware corporation (“Parent”), Morphogenesis, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHER |
|
| May 23, 2023 |
Exhibit 99.3 CohBar and Morphogenesis Merger Agreement Announcement Webcast Call Transcript TUESDAY, MAY 23, 2023 8:30am CORPORATE PARTICIPANTS Dr. Joseph J. Sarret, President and Chief Executive Officer of CohBar Dr. James Bianco, Chief Executive Officer of Morphogenesis PRESENTATION Operator Slide 1 Hello, and welcome to the CohBar and Morphogenesis conference call and webcast. As a brief remind |
|
| May 23, 2023 |
FORM OF PARENT SUPPORT AGREEMENT COHBAR, INC. SUPPORT AGREEMENT Exhibit 10.4 FORM OF PARENT SUPPORT AGREEMENT COHBAR, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of May 22, 2023 (the “Effective Date”), is made by and among CohBar, Inc., a Delaware corporation (“Parent”), Morphogenesis, Inc., a Delaware corporation (the “Company”), and the undersigned holder (“Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHER |
|
| May 23, 2023 |
[Remainder of page intentionally left blank.] Exhibit 10.8 May 22, 2023 Joseph J. Sarret Chief Executive Officer CohBar, Inc. Re: CohBar, Inc. Employee Retention Bonus Ladies and Gentlemen: Reference is made to that certain Executive Employment Agreement, dated as of April 26, 2021 (the “Employment Agreement”) by and between CohBar, Inc., a Delaware corporation (the “Company”) and Joseph J. Sarret (“you”). It is proposed that the Company ente |
|
| May 23, 2023 |
[Remainder of page intentionally left blank.] Exhibit 10.9 May 22, 2023 Mr. Jeffrey F. Biunno Chief Financial Officer CohBar, Inc. Re: CohBar, Inc. Employee Retention Bonus Ladies and Gentlemen: Reference is made to that certain Executive Employment Agreement, dated as of November 27, 2013, as amended (the “Employment Agreement”) by and between CohBar, Inc., a Delaware corporation (the “Company”) and Jeff Biunno (“you”). It is proposed that t |
|
| May 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2023 Date of Report (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 23, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of [], 2023, by and among CohBar, Inc., a Delaware corporation (the “Company”), K&V Investment Two, LLC, a Florida limited liability company and the Warrant Holders (as defined below). This Agreement is made pursuant to the Stock Purchase Agreement, dated as of May 22, 2023, between the Com |
|
| May 23, 2023 |
Exhibit 99.1 CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy ● Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulators ● Lead |
|
| May 23, 2023 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among COHBAR, INC., CHIMERA MERGECO, INC. and MORPHOGENESIS, INC. Dated as of May 22, 2023 TABLE OF CONTENTS Page Article I CERTAIN GOVERNANCE MATTERS 3 Section 1.1 Parent Matters 3 Section 1.2 Surviving Company Matters 3 Article II THE MERGER 4 Section 2.1 Incorporation of Merger Sub 4 Section 2.2 The Merger 4 Section 2.3 Closing 4 Section 2.4 Effec |
|
| May 23, 2023 |
[Remainder of page intentionally left blank.] Exhibit 10.8 May 22, 2023 Joseph J. Sarret Chief Executive Officer CohBar, Inc. Re: CohBar, Inc. Employee Retention Bonus Ladies and Gentlemen: Reference is made to that certain Executive Employment Agreement, dated as of April 26, 2021 (the “Employment Agreement”) by and between CohBar, Inc., a Delaware corporation (the “Company”) and Joseph J. Sarret (“you”). It is proposed that the Company ente |
|
| May 23, 2023 |
FORM OF CONTINGENT VALUE RIGHTS AGREEMENT Exhibit 10.6 FORM OF CONTINGENT VALUE RIGHTS AGREEMENT THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of [●], 2023, is entered into by and among CohBar, Inc., a Delaware corporation (“Public Company”), and [●], as initial Rights Agent (as defined herein). RECITALS WHEREAS, Public Company, Chimera MergeCo, Inc., a Delaware corporation and wholly owned subsidiary of Public Compa |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001- |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38326 COHBAR, INC. ( |
|
| March 9, 2023 |
Description of the Registrant’s Securities Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2022, CohBar, Inc. (the “Company,” “we” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. The following is a summary of our Common Stock and certain provisions of our Third Amende |
|
| February 8, 2023 |
US19249J3077 / Cohbar Inc / Barzilai Nir Yacov - AMENDMENT NO. 4 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 4)* Under the Securities Exchange Act of 1934 CohBar, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19249J307 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 8, 2023 |
US19249J3077 / Cohbar Inc / Cohen Pinchas - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 CohBar, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19249J307 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| December 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2022 CohBar, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 17, 2022 CohBar, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 8, 2022 |
Exhibit 99.1 CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., November 8, 2022 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough thera |
|
| September 22, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COHBAR, INC. CohBar, Inc., a corporation organized and existing under the General Corporation Law (the ?DGCL?) of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY: FIRST: The name of the corporation is CohBar, Inc. The Corporation?s original Certificate of Incorporation was filed with t |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 22, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 15, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 15, 2022 |
Exhibit 99.1 CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., August 15, 2022 ? CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in i |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| July 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 11, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 16, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 15, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 24, 2022 |
DEFA14A 1 ea160457-defa14acohbarinc.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 16, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 16, 2022 |
Exhibit 99.1 CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress Conference call and webcast today at 5:00 p.m. ET, May 16, 2022 MENLO PARK, Calif., May 16, 2022 ? CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics |
|
| May 12, 2022 |
DEFA14A 1 ea159638-defa14acohbar.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commis |
|
| April 22, 2022 |
DEF 14A 1 def14a0422cohbarinc.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Onl |
|
| April 12, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 29, 2022 |
Exhibit 99.1 CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update Conference call and webcast at 5:00 p.m. ET today, March 29, 2022 MENLO PARK, Calif., March 29, 2022 ? CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough thera |
|
| March 29, 2022 |
EXHIBIT 10.16 January 5, 2022 Via Email Kenneth Cundy Re: Terms of Transition and Resignation Dear Ken: This letter confirms the agreement (?Agreement?) between you and CohBar, Inc. (the ?Company?) concerning the terms of your transition and separation from the Company, and offers you certain benefits to which you would not otherwise be entitled, conditioned upon your provision of a general releas |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38326 COHBAR, INC. ( |
|
| March 29, 2022 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-248279 AMENDMENT NO. 1 DATED MARCH 29, 2022 to Prospectus Supplement dated September 3, 2020 (to Prospectus dated September 3, 2020) Up to $5,000,000 Common Stock This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated September 3, 2020 (File No. 333-248279), or the Prospectus Supplement. This Am |
|
| March 29, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 29, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 3, 2022 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| February 14, 2022 |
CWBR / CohBar Inc / CVI Investments, Inc. - SC 13G/A Passive Investment CUSIP No: 19249J109 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* CohBar, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19249J109 (CUSIP Number) Decembe |
|
| February 1, 2022 |
CWBR / CohBar Inc / Cohen Pinchas - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 CohBar, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19249J109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 1, 2022 |
CWBR / CohBar Inc / Barzilai Nir Yacov - AMENDMENT NO. 3 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 CohBar, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19249J109 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 13, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 15, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact |
|
| November 15, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 10, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 15, 2021 |
Exhibit 99.1 CohBar Reports Third Quarter 2021 Financial Results and Provides Business Update Company to host conference call at 5:00 p.m. ET MENLO PARK, Calif., November 15, 2021 ? CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the third q |
|
| November 8, 2021 |
CWBR / CohBar Inc / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 19249J109 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* CohBar, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 19249J109 (CUSIP Number) October |
|
| October 28, 2021 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CohBar, Inc. Warrant Shares: Initial Exercise Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial Exercise Date?) |
|
| October 28, 2021 |
Financial Statements and Exhibits, Other Events, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 28, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 28, 2021 |
20,833,334 Shares of Common Stock Warrants to Purchase up to 20,833,334 Shares of Common Stock 424B5 1 ea149512-424b5cohbar.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-248279 PROSPECTUS SUPPLEMENT (To Prospectus dated September 3, 2020) 20,833,334 Shares of Common Stock Warrants to Purchase up to 20,833,334 Shares of Common Stock We are offering 20,833,334 shares of our common stock and accompanying warrants to purchase up to 20,833,334 shares of our comm |
|
| October 28, 2021 |
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants Exhibit 99.1 CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants MENLO PARK, Calif., October 28, 2021 ? CohBar, Inc. (NASDAQ: CWBR) (the ?Company?), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the pricing of an underwritten public offering of 20,833,334 sh |
|
| October 28, 2021 |
Underwriting Agreement, dated October 28, 2021 Exhibit 1.1 COHBAR, INC. 20,833,334 Shares of Common Stock (par value $0.001 per share) and Warrants to Purchase 20,833,334 Shares of Common Stock Underwriting Agreement October 28, 2021 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: CohBar, Inc., a Delaware corpo |
|
| October 27, 2021 |
Subject to Completion, dated October 27, 2021 424B5 1 ea149214-424b5cohbar.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-248279 The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement and the accompanying prospectus are not an of |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 14, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 13, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 13, 2021 |
Exhibit 99.1 Breakthrough Mitochondrial Science A Source for Novel Therapeutics HCW Conference September 2021 Forward Looking Statements 2 This presentation contains forward - looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements are based only on our current beliefs, expectations and assumptions |
|
| September 9, 2021 |
Forms of Inducement Stock Option Agreements – Sarret Exhibit 99.1 COHBAR, INC. Inducement STOCK OPTION GRANT NOTICE (Time-Based) CohBar, Inc., a Delaware corporation (the ?Company?) hereby grants to Optionholder an option to purchase the number of shares of the Company?s common stock (?Common Stock?) set forth below (the ?Option?). The Option is subject to all of the terms and conditions as set forth herein, in the Option Agreement, and the Notice o |
|
| September 9, 2021 |
As filed with the Securities and Exchange Commission on September 9, 2021 As filed with the Securities and Exchange Commission on September 9, 2021 Registration No. |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 11, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 12, 2021 |
EXHIBIT 10.1 Executive Employment Agreement This Executive Employment Agreement (?Agreement?) is made by and between Joseph Sarret (?Executive?) and CohBar, Inc. (the ?Company?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?) and is effective as of the date it is signed by the Parties (the ?Effective Date?). Recitals WHEREAS, the Company desires to employ the E |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| August 10, 2021 |
Exhibit 99.2 CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity ? CB4211 was well-tolerated and appeared safe with no serious adverse events ? Robust reductions in ALT and AST ? Reduction in glucose and trend towards body weight reduction ? Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., August 10, 2 |
|
| August 10, 2021 |
EX-99.1 2 ea145151ex99-1cohbar.htm COHBAR, INC. PRESS RELEASE DATED AUGUST 10, 2021 Exhibit 99.1 CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., August 10, 2021 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chr |
|
| August 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 10, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 10, 2021 |
Exhibit 99.3 Breakthrough Mitochondrial Science A Source for Novel Therapeutics Q2 Investor Presentation August 2021 NASDAQ: CWBR Forward Looking Statements 2 This presentation contains forward - looking statements which are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements are based only on our current beliefs, expectati |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 16, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001- |
|
| May 17, 2021 |
Exhibit 99.1 CohBar Reports First Quarter 2021 Financial Results and Provides Business Update Company to host conference call at 5:00 p.m. ET MENLO PARK, Calif., May 17, 2021 ? CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the first quarte |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| May 17, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 17, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 30, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Definitive Proxy State |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 26, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 30, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 30, 2021 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38326 COHBAR, INC. ( |
|
| March 30, 2021 |
Exhibit 99.1 CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., March 30, 2021 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for t |
|
| March 30, 2021 |
Description of the Registrant’s Securities. Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2020, CohBar, Inc. (the ?Company,? ?we? or ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. The following is a summary of our Common Stock and certain provisions of our Third Amende |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 3)* Under the Securities Exchange Act of 1934 CohBar, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19249J109 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 28, 2021 |
COHBAR, INC. 1455 Adams Drive, Suite 2050 Menlo Park, CA 94025 January 28, 2021 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ada Sarmento Office of Life Sciences Re: CohBar, Inc. Registration Statement on Form S-3 Filed January 22, 2021 File No. 333-252331 Via EDGAR - Acceleration Request Requested Date: January |
|
| January 22, 2021 |
As filed with the Securities and Exchange Commission on January 22, 2021 Registration No. |
|
| January 6, 2021 |
As filed with the Securities and Exchange Commission on January 6, 2021 Registration No. |
|
| December 22, 2020 |
8-K 1 ea131955-8kcohbarinc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 18, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other juris |
|
| December 22, 2020 |
Exhibit 4.1 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS |
|
| December 22, 2020 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT THIS SUBSCRIPTION AGREEMENT (the “Agreement”) by and between CohBar, Inc., a Delaware corporation (the “Company”), and the undersigned individual, corporation, limited liability company, partnership, trust or employee benefit plan executing this Agreement as the investor (the “Investor”), provides as follows: Recitals A. This Agreement is made in connection with |
|
| November 16, 2020 |
Exhibit 99.1 CohBar Reports Third Quarter 2020 Financial Results and Provides Business Update Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., November 16, 2020 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for |
|
| November 16, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 16, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 16, 2020 |
10-Q 1 f10q0920cohbarinc.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| September 8, 2020 |
CWBR / CohBar Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 31, 2020 |
CORRESP 1 filename1.htm COHBAR, Inc. 1455 Adams Drive Suite 2050 Menlo Park, CA 94025 August 31, 2020 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Deanna Virginio Office of Life Sciences Re: CohBar, Inc Registration Statement on Form S-3 Filed August 24, 2020 File No. 333-248279 Via EDGAR - Acceleration Request |
|
| August 26, 2020 |
Exhibit 4.1 COMMON STOCK PURCHASE WARRANT CohBar, Inc. Warrant Shares: Initial Exercise Date: , 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) |
|
| August 26, 2020 |
Underwriting Agreement, dated August 26, 2020 EX-1.1 2 ea126028ex1-1cohbarinc.htm UNDERWRITING AGREEMENT, DATED AUGUST 26, 2020 Exhibit 1.1 12,300,000 SHARES of Common Stock and 12,300,000 Warrants (EXercisable for 9,225,000 warrant shares) of COHBAR, INC. UNDERWRITING AGREEMENT August 26, 2020 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 Sa |
|
| August 26, 2020 |
424B5 1 ea126073-424b5cohbar.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-221724 PROSPECTUS SUPPLEMENT (To prospectus dated December 1, 2017) 12,300,000 Shares of Common Stock Warrants to Purchase up to 9,225,000 Shares of Common Stock $1.22 per Unit We are offering 12,300,000 shares of our common stock and warrants to purchase up to 9,225,000 shares of our commo |
|
| August 26, 2020 |
CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants Exhibit 99.1 CohBar Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants MENLO PARK, Calif., August 26, 2020 – CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the pricing of an underwritten public offering of 12,300,000 uni |
|
| August 26, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 26, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 25, 2020 |
Subject to Completion Preliminary Prospectus Supplement dated August 25, 2020 Filed Pursuant to Rule 424(b)(5) Registration No. 333-221724 The information in this prospectus supplement is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus supplement and the accompanying prospectus are not an offer to sell these securities and it is not soliciting a |
|
| August 24, 2020 |
Exhibit 4.4 COHBAR, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 5 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EXECUTION AND AU |
|
| August 24, 2020 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] COHBAR, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD TO MATURITY IS % |
|
| August 24, 2020 |
As filed with the Securities and Exchange Commission on August 24, 2020 Registration No. |
|
| August 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q R QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact name |
|
| August 13, 2020 |
EX-99.1 2 ea124904ex99-1cohbar.htm COHBAR, INC. PRESS RELEASE DATED AUGUST 13, 2020 Exhibit 99.1 CohBar Reports Second Quarter 2020 Financial Results and Provides Business Update New positive preliminary preclinical results in ARDS model Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., August 13, 2020 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology comp |
|
| August 13, 2020 |
EX-10.3 3 f10q0620ex10-3cohbarinc.htm FORM OF NONTRANSFERABLE COMMON STOCK PURCHASE WARRANT ISSUED AUGUST 2020 Exhibit 10.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMI |
|
| August 13, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 13, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 13, 2020 |
Exhibit 10.2 COHBAR, INC. SECOND AMENDMENT TO 8% UNSECURED PROMISSORY NOTE AND NONTRANSFERABLE COMMON STOCK PURCHASEWARRANT This Second Amendment to 8% Unsecured Promissory Note and Nontransferable Common Stock Purchase Warrant, dated as of August [], 2020 (this “Amendment”), amends that certain 8% Unsecured Promissory Note Due 2021, as amended by the Original Amendment (as defined below) (the “No |
|
| July 9, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 6, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 9, 2020 |
CohBar, Inc. press release dated July 7, 2020. Exhibit 3.1 CohBar Resumes CB4211 Phase 1b Clinical Trial MENLO PARK, Calif., July 7, 2020 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it has resumed the Phase 1b stage of its Phase 1a/1b clinical trial of CB4211, its lead candidate for the treatment of n |
|
| June 23, 2020 |
Exhibit 99.5 THIRD AMENDMENT TO AMENDED AND RESTATED 2011 EQUITY INCENTIVE PLAN 1. Section 3(a) of the Plan is deleted in its entirety and replaced by the following new provision: Share Reserve; ISO Limitation. Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards from and after the Effective Date |
|
| June 23, 2020 |
As filed with the Securities and Exchange Commission on June 23, 2020 Registration No. |
|
| June 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 16, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 18, 2020 |
EX-3.1 2 ea122842ex3-1cohbar.htm AMENDMENT TO THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1 Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of CohBar Inc. CohBar, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (“DGCL”), DOES HEREBY CERTIFY that: FIRST: |
|
| May 27, 2020 |
Up to $20,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No.: 333-221724 PROSPECTUS SUPPLEMENT (To Prospectus dated December 1, 2017) Up to $20,000,000 Common Stock We have entered into an At-the-Market Sales Agreement, or the Sales Agreement, with Virtu Americas LLC, or Virtu, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supplement and the accompanying prosp |
|
| May 27, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 27, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 27, 2020 |
Exhibit 1.1 COHBAR, INC. Shares of Common Stock (par value $0.001 per share) At-the-Market Sales Agreement May 27, 2020 Virtu Americas LLC One Liberty Plaza 165 Broadway New York, NY 10006 Ladies and Gentlemen: CohBar, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Virtu Americas LLC (the “Agent”), as follows: 1. Issuance and Sale of Shares. The Compan |
|
| May 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 14, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 14, 2020 |
Quarterly Report - QUARTERLY REPORT 10-Q 1 f10q0320cohbarinc.htm QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| May 14, 2020 |
Exhibit 99.1 CohBar Reports First Quarter 2020 Financial Results and Provides Business Update Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., May 14, 2020 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the |
|
| May 13, 2020 |
EX-99.1 2 ea121684-8kex991cohbar.htm COHBAR, INC. PRESS RELEASE DATED MAY 13, 2020. Exhibit 99.1 CohBar’s Chief Operating Officer Jon Stern Plans to Step Down from Management Role Former senior executive to continue on CohBar Board of Directors MENLO PARK, Calif., May 13, 2020 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat |
|
| May 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 13, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 29, 2020 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Definitive Proxy State |
|
| April 14, 2020 |
CWBR / CohBar Inc. PRE 14A - - PRELIMINARY PROXY STATEMENT United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 30, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 12, 2020 |
Description of the Registrant’s Securities. EX-4.1 2 f10k2019ex4-1cohbar.htm DESCRIPTION OF THE REGISTRANT'S SECURITIES Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of December 31, 2019, CohBar, Inc. (the “Company,” “we” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934: our common stock. The following |
|
| March 12, 2020 |
Exhibit 10.26 COHBAR, INC. AMENDMENT TO 8% UNSECURED PROMISSORY NOTE AND NONTRANSFERABLE COMMON STOCK PURCHASEWARRANT This Amendment to 8% Unsecured Promissory Note and Nontransferable Common Stock Purchase Warrant, dated as of February 25, 2020 (this “Amendment”), amends that certain 8% Unsecured Promissory Note Due 2021 (the “Note”) and the Nontransferable Common Stock Purchase Warrant (the “War |
|
| March 12, 2020 |
Exhibit 99.1 CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., March 12, 2020 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases and extend healthy lifespan, today reported its financial result |
|
| March 12, 2020 |
10-K 1 f10k2019cohbarinc.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commi |
|
| March 12, 2020 |
Exhibit 10.27 COHBAR, INC. AMENDMENT TO COMMON STOCK PURCHASE WARRANT This Amendment to Common Stock Purchase Warrant, dated as of February 25, 2020 (this “Amendment”), amends that certain Common Stock Purchase Warrant (the “Warrant”) issued under that certain Subscription Agreement (the “Subscription Agreement”) dated July 14, 2017, by and between CohBar, Inc., a Delaware corporation (the “Compan |
|
| March 12, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 12, 2020 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 7, 2019 |
CWBR / CohBar Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38326 COHBAR, INC. (Exact |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 6, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 001-38326 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 6, 2019 |
EX-99.1 2 f8k110619ex99-1cohbarinc.htm COHBAR, INC. PRESS RELEASE DATED NOVEMBER 6, 2019. Exhibit 99.1 CohBar Reports Third Quarter 2019 Financial Results and Business Update Company to host conference call and webcast today, November 6th, at 5:00 p.m. ET Menlo Park, California – November 6, 2019 - CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based th |
|
| October 23, 2019 |
8-K 1 f8k101819cohbarinc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 18, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdic |
|
| August 9, 2019 |
EX-10.3 2 f10q0619ex10-3cohbar.htm ADDENDUM TO THE EXECUTIVE EMPLOYMENT AGREEMENT, DATED NOVEMBER 27, 2013, BY AND BETWEEN COHBAR, INC. AND JEFFREY F. BIUNNO Exhibit 10.3 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Second Amendment to Executive Employment Agreement (this “Amendment”), dated as of June 4, 2019, amends that certain Executive Employment Agreement (the “Agreement”), dated |
|
| August 9, 2019 |
CWBR / CohBar Inc. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-55334 COHBAR, INC. (Exact name |
|
| August 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 7, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| August 7, 2019 |
Exhibit 99.1 CohBar Reports Second Quarter 2019 Financial Results and Business Update Company to host conference call and webcast today, August 7th, at 5:00 p.m. EDT Menlo Park, California – August 7, 2019 - CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today reported |
|
| July 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 17, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 21, 2019 |
CohBar, Inc. Employee Stock Purchase Plan. Exhibit 10.1 COHBAR, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Purpose of the Plan. CohBar, Inc. (the “Company”) believes that ownership of shares of its common stock by employees of the Company and its Participating Subsidiaries (as defined below) is desirable as an incentive to better performance and improvement of profits, and as a means by which employees may share in the Company’s growth and succe |
|
| June 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 18, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2019 |
CWBR / CohBar Inc. 10-Q Quarterly Report QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-55334 COHBAR, INC. (Exact name |
|
| May 8, 2019 |
EX-10.2 2 f10q0319ex10-2cohbarinc.htm EXECUTIVE EMPLOYMENT AGREEMENT, DATED MAY 6, 2019, BY AND BETWEEN COHBAR, INC. AND STEVEN B. ENGLE Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of May 6, 2019 (the “Effective Date’’) by and between CohBar, Inc. (the “Company”) and Steven B. Engle (“You”) in order to provide the general |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 7, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| May 7, 2019 |
EX-99.1 2 f8k050719ex99-1cohbar.htm COHBAR, INC. PRESS RELEASE DATED MAY 7, 2019 Exhibit 99.1 CohBar Reports First Quarter 2019 Financial Results and Business Update Company to host conference call and webcast today, May 7, at 5:00 p.m. EDT Menlo Park, California – May 7, 2019 - CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to |
|
| May 7, 2019 |
8-K 1 f8k050619cohbarinc.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 6, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction |
|
| May 3, 2019 |
CohBar to Resume its Phase 1a/1b Clinical Trial EX-99.1 2 f8k050319ex99-1cohbarinc.htm COHBAR, INC. PRESS RELEASE DATED MAY 3, 2019 Exhibit 99.1 CohBar to Resume its Phase 1a/1b Clinical Trial Menlo Park, California – May 3, 2019 - CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases and extend healthy lifespan, today announced that it has concluded i |
|
| May 3, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 3, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 24, 2019 |
United States Securities and Exchange Commission Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant S Filed by a Party other than the Registrant £ Check the appropriate box: £ Preliminary Proxy Statement £ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) S Definitive Proxy State |
|
| April 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 19, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 6, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 11, 2019 |
Exhibit 10.1 Dr. Philippe Calais 2040 Alta Meadows Lane #1609 Del Ray Beach, Florida 33333 April 6, 2019 Re: Interim Chief Executive Officer Agreement Extension Dear Philippe: Reference is made to that Interim Chief Executive Officer Agreement (the “Agreement”), dated December 7, 2018, by and between you and CohBar, Inc. (the “Company”). Capitalized terms used herein but not defined shall the mean |
|
| March 18, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 18, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 18, 2019 |
CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update Exhibit 99.1 CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update Menlo Park, California – March 18, 2019 - CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported its financial results for the fourth quarter ended December 31, 2018. “We continue to focus on gett |
|
| March 18, 2019 |
EX-10.20 2 f10k2018ex10-20cohbarinc.htm P. CALAIS INTERIM CEO AGREEMENT (EXECUTION VERSION) Exhibit 10.20 Dr. Philippe Calais 2040 Alta Meadows Lane #1609 Del Ray Beach, Florida 33333 December 7, 2018 Re: Interim Chief Executive Officer Agreement Dear Philippe: On behalf of Cohbar, Inc. (the “Company”), I am pleased to offer you the position of Interim Chief Executive Officer of the Company on the |
|
| March 18, 2019 |
10-K 1 f10k2018cohbarinc.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commi |
|
| March 18, 2019 |
Letter Agreement, dated January 10, 2019, by and between CohBar, Inc. and Simon Allen. Exhibit 10.21 January 10, 2019 Mr. Simon Allen 16870 Camino Lago de Cristal Rancho Santa Fe CA 92067 Re: Stock Option Agreement Dear Simon, Reference is made to that certain Stock Option Grant Notice and Agreement, dated March 7, 2016 (the “Option Agreement”), by and between you and CohBar, Inc., a Delaware corporation (the “Company”). Capitalized terms used herein shall have the meanings given to |
|
| February 12, 2019 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 11, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 11, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 8, 2019 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| February 11, 2019 |
CWBR / CohBar Inc. / FITZGERALD ALBION - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 CohBar, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 19249J109 (CUSIP Number) December 31, 2018 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| December 18, 2018 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 17, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 10, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 6, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 10, 2018 |
Exhibit 10.1 Dr. Philippe Calais 2040 Alta Meadows Lane #1609 Del Ray Beach, Florida 33333 December 7, 2018 Re: Interim Chief Executive Officer Agreement Dear Philippe: On behalf of Cohbar, Inc. (the “Company”), I am pleased to offer you the position of Interim Chief Executive Officer of the Company on the terms and conditions set forth in this letter agreement (this “Agreement”). You have agreed |
|
| November 14, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 14, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 14, 2018 |
EX-99.1 2 f8k111418ex99-1cohbarinc.htm COHBAR, INC. PRESS RELEASE DATED NOVEMBER 14, 2018 Exhibit 99.1 CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update Will Host Conference Call on November 14, 2018 at 5:00 p.m. Eastern Time Menlo Park, California – November 14, 2018 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based |
|
| November 14, 2018 |
CWBR / CohBar Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-55334 COHBAR, INC. (Exact |
|
| November 5, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 5, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 5, 2018 |
Exhibit 99.1 CohBar Provides Update on CB4211 Clinical Trial CB4211 Phase 1 Clinical Trial Temporarily Suspended to Address Injection Site Reactions Will Host Conference Call on November 6, 2018 at 11:00 a.m. Eastern Time MENLO PARK, Calif., Nov. 5, 2018 - CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related dise |
|
| August 14, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 14, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 14, 2018 |
CohBar Announces Second Quarter 2018 Financial Results Exhibit 99.1 CohBar Announces Second Quarter 2018 Financial Results Menlo Park, California – August 14, 2018 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported financial results for the second quarter ended June 30, 2018. “CohBar had a stellar second quarter as we joined the Russell 2 |
|
| August 14, 2018 |
CWBR / CohBar Inc. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-55334 COHBAR, INC. (Exact name |
|
| August 10, 2018 |
COHBAR, INC. 780,500 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-226433 PROSPECTUS COHBAR, INC. 780,500 Shares of Common Stock This prospectus relates to 780,500 shares of our common stock, which may be offered for sale from time to time by the selling stockholders identified in this prospectus. These shares are issuable upon the exercise of certain common stock purchase warrants (the “Warrants”). Each Warra |
|
| August 7, 2018 |
CohBar, Inc. 1455 Adams Dr., Suite 2050 Menlo Park, CA 94025 August 7, 2018 VIA EDGAR AND E-MAIL Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ada Sarmento Re: CohBar, Inc. Registration Statement on Form S-3 (Registration No. 333-226433) Filed July 30, 2018 Acceleration Request Requested Date: August 9, 2018 Requested Time: 4: |
|
| July 30, 2018 |
As filed with the Securities and Exchange Commission on July 30, 2018 Registration No. |
|
| July 30, 2018 |
EX-99.4 4 fs8072618ex99-4cohbarinc.htm SECOND AMENDMENT TO AMENDED AND RESTATED 2011 EQUITY INCENTIVE PLAN. Exhibit 99.4 SECOND AMENDMENT TO AMENDED AND RESTATED 2011 EQUITY INCENTIVE PLAN 1. Section 3(a) of the Plan is deleted in its entirety and replaced by the following new provision: Share Reserve. Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares o |
|
| July 30, 2018 |
CWBR / CohBar Inc. REGISTRATION STATEMENT S-3 1 fs32018cohbarinc.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on July 30, 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CohBar, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 26-1299952 (State or Other Jurisdiction of |
|
| July 12, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 12, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 12, 2018 |
EX-99.1 2 f8k071218ex99-1cohbarinc.htm COHBAR, INC. PRESS RELEASE DATED JULY 12, 2018 Exhibit 99.1 CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH Menlo Park, California – July 12, 2018 – CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to trea |
|
| June 27, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 27, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 27, 2018 |
CohBar Completes Sale of $20 Million Under Controlled Equity Offering EX-99.1 2 f8k062718ex99-1cohbarinc.htm COHBAR, INC. PRESS RELEASE DATED JUNE 27, 2018 Exhibit 99.1 CohBar Completes Sale of $20 Million Under Controlled Equity Offering Menlo Park, California – June 27, 2018 – CohBar, Inc. (NASDAQ: CWBR), an innovative biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that it has completed sales |
|
| June 21, 2018 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 19, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 12, 2018 |
Up to $20,000,000 Common Stock FILED PURSUANT TO RULE 424(b)(5) REGISTRATION NO.: 333-221724 PROSPECTUS SUPPLEMENT (To Prospectus dated December 1, 2017) Up to $20,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, par value $0.001 per share, offered by this prospectus supple |
|
| June 12, 2018 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 12, 2018 (Date of earliest event reported) COHBAR, INC. (Exact name of registrant as specified in its charter) Delaware 000-55334 26-1299952 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 12, 2018 |
Exhibit 10.1 COHBAR, INC. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement June 12, 2018 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: CohBar, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issuance and Sale of Shares |
